SUMO-modifying Huntington's disease

被引:12
|
作者
Soares, Ericks S. [1 ]
Prediger, Rui D. [1 ,2 ]
Brocardo, Patricia S. [2 ]
Cimarosti, Helena, I [1 ,2 ]
机构
[1] Fed Univ Santa Catarina UFSC, Postgrad Program Pharmacol, Florianopolis, SC, Brazil
[2] Univ Fed Santa Catarina, Postgrad Program Neurosci, Florianopolis, SC, Brazil
来源
IBRO NEUROSCIENCE REPORTS | 2022年 / 12卷
关键词
Huntingtin; Huntington's disease; Neurodegeneration; Post-translational modification; SUMO; SUMOylation; MUTANT-HUNTINGTIN; POSTTRANSLATIONAL MODIFICATIONS; PROTEIN; SUMOYLATION; RHES; AGGREGATION; DESUMOYLATION; DEGENERATION; PATHOGENESIS; DEGRADATION;
D O I
10.1016/j.ibneur.2022.03.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Small ubiquitin-like modifiers, SUMOs, are proteins that are conjugated to target substrates and regulate their functions in a post-translational modification called SUMOylation. In addition to its physiological roles, SUMOylation has been implicated in several neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's diseases (HD). HD is a neurodegenerative monogenetic autosomal dominant disorder caused by a mutation in the CAG repeat of the huntingtin (htt) gene, which expresses a mutant Htt protein more susceptible to aggregation and toxicity. Besides Htt, other SUMO ligases, enzymes, mitochondrial and autophagic components are also important for the progression of the disease. Here we review the main aspects of Htt SUMOylation and its role in cellular processes involved in the pathogenesis of HD.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [11] Huntington's Disease Community Perspectives on Desired Characteristics of Disease Modifying Therapies
    Gornick, Michele C.
    Ryan, Kerry A.
    Dayalu, Praveen
    Carlozzi, Noelle E.
    Albin, Roger L.
    Zahuranec, Darin B.
    TREMOR AND OTHER HYPERKINETIC MOVEMENTS, 2021, 11 : 1 - 9
  • [12] Difficulty modifying a sustained motor response in prodromal Huntington's disease
    Mickes, Laura
    Wixted, John T.
    Peavy, Guerry M.
    Jacobson, Mark W.
    Goldstein, Jody L.
    Corey-Bloom, Jody
    JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 2013, 35 (01) : 35 - 40
  • [13] Huntington's disease: progress toward effective disease-modifying treatments and a cure
    Johnson, Carl D.
    Davidson, Beverly L.
    HUMAN MOLECULAR GENETICS, 2010, 19 : R98 - R102
  • [14] Nanoparticles as disease-modifying mediators for brain therapy: focus on Huntington's disease
    Godinho, B. M. D. C.
    Ogier, J. R.
    Darcy, R.
    O'Driscoll, C. M.
    Cryan, J. F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S52 - S53
  • [15] Nanoparticles as disease-modifying mediators for brain therapy: focus on Huntington's disease
    Godinho, B. M. D. C.
    Ogier, J. R.
    Darcy, R.
    O'Driscoll, C. M.
    Cryan, J. F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S545 - S545
  • [16] SUMO has big role in Huntington's pathology
    Butcher, J
    LANCET NEUROLOGY, 2004, 3 (05): : 262 - 262
  • [17] Questions swirl around failures of disease-modifying Huntington's drugs
    Sheridan, Cormac
    NATURE BIOTECHNOLOGY, 2021, 39 (06) : 650 - 652
  • [18] Questions swirl around failures of disease-modifying Huntington’s drugs
    Cormac Sheridan
    Nature Biotechnology, 2021, 39 : 650 - 652
  • [19] Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies
    Dash, Deepa
    Mestre, Tiago A.
    NEUROTHERAPEUTICS, 2020, 17 (04) : 1645 - 1659
  • [20] Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies
    Deepa Dash
    Tiago A. Mestre
    Neurotherapeutics, 2020, 17 : 1645 - 1659